Proxied therapeutic inhibition on sclerostin and atrial fibrillation risk - PubMed
4 hours ago
- #sclerostin inhibition
- #Mendelian randomization
- #atrial fibrillation risk
- Sclerostin (SOST) inhibition is used to treat osteoporosis but has uncertain cardiovascular effects.
- Genetic variants mimicking SOST inhibition, particularly via the B4GALNT3 gene, were linked to both increased bone mineral density and higher atrial fibrillation (AF) risk.
- Mendelian randomization analyses showed proxied SOST inhibition significantly raises AF risk (OR = 1.353, P = 0.009), highlighting a potential side effect for patients.